Granules India Limited
2,272words
3turns
0analyst exchanges
0executives
Key numbers — 40 extracted
18.0%
53.7%
46.6%
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
Speaking time
1
1
1
Advertisement
Opening remarks
As Encl
Granules India Limited Q3 Earnings Presentation Granules India Limited Q3 Earnings Presentation 1 Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could ca
Total GPI products include
ANDA/Dossier filed - Therapeutic area wise CII – 7 PFOS – 4 Liquid Orals – 3 Analgesics Central Nervous System Anti-diabetics IMS value for these products is approximately $9,229 Mn *Source IMS MAT Nov 2021 Mineral supplements 5 Cardiovasculars Anti Histamines Anti gout Antitussives Other areas 4 3 3 8 7 9 21 15 7 Revenue trend – percentage share from Core and Other Molecules Core Others Para MF IBU GGF MCB Others 14% 14% 17% 14% 15% 17% 16% 15% 19% 16% 86% 86% 83% 86% 85% 83% 84% 85% 81% 84% 14% 34% 1% 5% 17% 29% 33% 17% 26% 6% 4% 19% 21% 21% 34% 29% 34% 34% 33% 30% 15% 18% 5% 3% 25% 19% 23% 17% 29% 14% 16% 3% 3% 3% 18% 16% 19% 3% 2% 13% 3% 6% 26% 26% 17% 4% 5% 5% 1% 14% 34% 37% 3% 14% FY18A FY'19A FY'20A FY'21A YTD Dec'21 FY18 FY'19 FY'20 FY'21 YTD Dec'21 Core includes Paracetamol, Metformin, Ibuprofen, Methocarbamol and Guaifenesin 8 5-year trajectory: Key Ratios and Cash Flow Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) (In ₹ Mn) 10,000 9,000 8,0
Corporate address
Floor 2 Block 3 My Home Hub Madhapur Hyderabad 500081 CIN: L24110TG1991PLC012471 Voice: +91 40 69043600 Fax: +91 40 69043602 www.granulesindia.com 532482 GRANULES GRAN:IN GRAN:NS
Advertisement